Literature DB >> 17987392

Trends in breast-conserving surgery in Denmark, 1982-2002.

Thomas P Ahern1, Heidi Larsson, Jens Peter Garne, Deirdre P Cronin-Fenton, Henrik Toft Sørensen, Timothy L Lash.   

Abstract

Using hospital discharge data from the counties in Northern Denmark and the Danish Cancer Registry, we examined the trend in the prevalence of breast-conserving surgery (BCS) to treat primary breast cancer from 1982 through 2002, with an emphasis on publications that may have influenced surgical practice in Denmark. Overall, the prevalence of BCS increased from less than 1% of breast cancer operations in 1982 to approximately 25% by 2002. The rise in prevalence was most pronounced for the treatment of young women and women with early-stage breast cancer. Of three pivotal clinical trials, the most significant trigger of the upward trend appeared to be a study conducted by the Danish Breast Cancer Cooperative Group, published in 1988. After 1988, there was a steep rise in the prevalence of BCS. By 2002, BCS prevalence appeared to reach a threshold at 25% of breast cancer operations, seemingly defined by the proportion of new breast cancer cases who are good candidates for BCS.

Entities:  

Mesh:

Year:  2007        PMID: 17987392     DOI: 10.1007/s10654-007-9207-1

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  17 in total

1.  Conservative treatment of breast carcinoma--review of 25 years follow up.

Authors:  S Mustakallio
Journal:  Clin Radiol       Date:  1972-01       Impact factor: 2.350

2.  Results of treatment of carcinoma of the breast by local excision.

Authors:  G Crile; S O Hoerr
Journal:  Surg Gynecol Obstet       Date:  1971-05

3.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

Authors:  J A van Dongen; A C Voogd; I S Fentiman; C Legrand; R J Sylvester; D Tong; E van der Schueren; P A Helle; K van Zijl; H Bartelink
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

4.  Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer.

Authors:  K W Andersen; H T Mouridsen
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

5.  Reduced mortality for women with mammography-detected breast cancer in east Denmark and south Sweden.

Authors:  L H Christensen; G Engholm; R Cortes; J Ceberg; U Tange; M Andersson; A Bladström; H T Mouridsen; T Möller; Hans Storm
Journal:  Eur J Cancer       Date:  2006-09-20       Impact factor: 9.162

6.  Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.

Authors:  M Blichert-Toft; C Rose; J A Andersen; M Overgaard; C K Axelsson; K W Andersen; H T Mouridsen
Journal:  J Natl Cancer Inst Monogr       Date:  1992

7.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.

Authors:  B Fisher; S Anderson; C K Redmond; N Wolmark; D L Wickerham; W M Cronin
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 8.  Breast cancer surgery: a century after Halsted.

Authors:  U Veronesi; S Zurrida
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

9.  Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast.

Authors:  U Veronesi; R Saccozzi; M Del Vecchio; A Banfi; C Clemente; M De Lena; G Gallus; M Greco; A Luini; E Marubini; G Muscolino; F Rilke; B Salvadori; A Zecchini; R Zucali
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

10.  Do changes in surgical procedures for breast cancer have consequences for hospital mean length of stay? A study of women operated on for breast cancer in Sweden, 1980-95.

Authors:  Rikard Lindqvist; Torgil R Möller; Magnus Stenbeck; Finn Diderichsen
Journal:  Int J Technol Assess Health Care       Date:  2002       Impact factor: 2.188

View more
  6 in total

1.  Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.

Authors:  Deirdre P Cronin-Fenton; Ylva Hellberg; Kristina L Lauridsen; Thomas P Ahern; Jens Peter Garne; Carol Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Acta Oncol       Date:  2011-11-30       Impact factor: 4.089

2.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Jens Peter Garne; Henrik Toft Sørensen; Ylva Hellberg; Mariann Christensen; Lars Pedersen; Stephen Hamilton-Dutoit
Journal:  J Natl Cancer Inst       Date:  2011-02-15       Impact factor: 13.506

3.  Survival of women with breast cancer in central and northern Denmark, 1998-2009.

Authors:  Lone Winther Lietzen; Gitte Vrelits Sørensen; Anne Gulbech Ording; Jens Peter Garne; Peer Christiansen; Mette Nørgaard; Jacob Jacobsen
Journal:  Clin Epidemiol       Date:  2011-07-21       Impact factor: 4.790

4.  Impact of surgical intervention trials on healthcare: A systematic review of assessment methods, healthcare outcomes, and determinants.

Authors:  Juliëtte J C M van Munster; Amir H Zamanipoor Najafabadi; Nick P de Boer; Wilco C Peul; Wilbert B van den Hout; Peter Paul G van Benthem
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

5.  Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study.

Authors:  Rune Gärtner; Deirdre Cronin-Fenton; Heidi H Hundborg; Lars Pedersen; Timothy L Lash; Henrik Toft Sørensen; Niels Kroman
Journal:  BMC Surg       Date:  2010-01-24       Impact factor: 2.102

6.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Authors:  T L Lash; L Pedersen; D Cronin-Fenton; T P Ahern; C L Rosenberg; K L Lunetta; R A Silliman; S Hamilton-Dutoit; J P Garne; M Ewertz; H T Sørensen
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.